scholarly journals Chronic but not intermittent infection withPseudomonas aeruginosais associated with global changes of the lung microbiome in cystic fibrosis

2017 ◽  
Vol 50 (4) ◽  
pp. 1701086 ◽  
Author(s):  
Sébastien Boutin ◽  
Simon Y. Graeber ◽  
Mirjam Stahl ◽  
A. Susanne Dittrich ◽  
Marcus A. Mall ◽  
...  
2021 ◽  
Author(s):  
Rebekah A. Jones ◽  
Holly Shropshire ◽  
Caimeng Zhao ◽  
Andrew Murphy ◽  
Ian Lidbury ◽  
...  

AbstractPseudomonas aeruginosa is a nosocomial pathogen with a prevalence in immunocompromised individuals and is particularly abundant in the lung microbiome of cystic fibrosis patients. A clinically important adaptation for bacterial pathogens during infection is their ability to survive and proliferate under phosphorus-limited growth conditions. Here, we demonstrate that P. aeruginosa adapts to P-limitation by substituting membrane glycerophospholipids with sugar-containing glycolipids through a lipid renovation pathway involving a phospholipase and two glycosyltransferases. Combining bacterial genetics and multi-omics (proteomics, lipidomics and metatranscriptomic analyses), we show that the surrogate glycolipids monoglucosyldiacylglycerol and glucuronic acid-diacylglycerol are synthesised through the action of a new phospholipase (PA3219) and two glycosyltransferases (PA3218 and PA0842). Comparative genomic analyses revealed that this pathway is strictly conserved in all P. aeruginosa strains isolated from a range of clinical and environmental settings and actively expressed in the metatranscriptome of cystic fibrosis patients. Importantly, this phospholipid-to-glycolipid transition comes with significant ecophysiological consequence in terms of antibiotic sensitivity. Mutants defective in glycolipid synthesis survive poorly when challenged with polymyxin B, a last-resort antibiotic for treating multi-drug resistant P. aeruginosa. Thus, we demonstrate an intriguing link between adaptation to environmental stress (nutrient availability) and antibiotic resistance, mediated through membrane lipid renovation that is an important new facet in our understanding of the ecophysiology of this bacterium in the lung microbiome of cystic fibrosis patients.


PLoS ONE ◽  
2016 ◽  
Vol 11 (8) ◽  
pp. e0160726 ◽  
Author(s):  
Giovanni Bacci ◽  
Patrizia Paganin ◽  
Loredana Lopez ◽  
Chiara Vanni ◽  
Claudia Dalmastri ◽  
...  

PLoS ONE ◽  
2016 ◽  
Vol 11 (6) ◽  
pp. e0156807 ◽  
Author(s):  
Giovanni Bacci ◽  
Patrizia Paganin ◽  
Loredana Lopez ◽  
Chiara Vanni ◽  
Claudia Dalmastri ◽  
...  

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Eva Vandeplassche ◽  
Andrea Sass ◽  
Astrid Lemarcq ◽  
Ajai A. Dandekar ◽  
Tom Coenye ◽  
...  

Biofilm ◽  
2020 ◽  
Vol 2 ◽  
pp. 100031
Author(s):  
Eva Vandeplassche ◽  
Andrea Sass ◽  
Lisa Ostyn ◽  
Mette Burmølle ◽  
Kasper Nørskov Kragh ◽  
...  

2021 ◽  
pp. 00731-2020
Author(s):  
Anne H. Neerincx ◽  
Katrine Whiteson ◽  
Joann L. Phan ◽  
Paul Brinkman ◽  
Mahmoud I. Abdel-Aziz ◽  
...  

RationaleTargeted cystic fibrosis (CF) therapy with lumacaftor/ivacaftor partly restores chloride channel function and improves epithelial fluid transport in the airways. Consequently, changes in the microbiome that is adapted to CF lungs may occur.ObjectivesTo investigate the effects of lumacaftor/ivacaftor on respiratory microbial composition and microbial metabolic activity by repeatedly sampling the lower respiratory tract.MethodsThis was a single-center longitudinal observational cohort study in adult CF patients with a homozygous Phe508del mutation. Lung function measurements and microbial cultures of sputum were performed as part of routine care. An oral and nasal wash, and a breath sample were collected before and every 3 months after starting therapy, up to 1 year.ResultsTwenty patients were included in this study. Amplicon 16S RNA and metagenomics sequencing revealed that Pseudomonas aeruginosa was most abundant in sputum and seemed to decrease after 6 months of treatment, although this did not reach statistical significance after correction for multiple testing. Two types of untargeted metabolomics analyses in sputum showed a change in metabolic composition between 3 and 9 months that almost returned to baseline levels after 12 months of treatment. The volatile metabolic composition of breath was significantly different after 3 months and remained different from baseline until 12 months follow up.ConclusionsAfter starting CF transmembrane conductance regulator (CFTR) modulating treatment in CF patients with a homozygous Phe508del mutation, a temporary and moderate change in lung microbiome is observed, which is mainly characterised by a reduction in the relative abundance of Pseudomonas aeruginosa.


2019 ◽  
Vol 201 (11) ◽  
Author(s):  
Jessie E. Scott ◽  
George A. O’Toole

ABSTRACTThe streptococci are increasingly recognized as a core component of the cystic fibrosis (CF) lung microbiome, yet the role that they play in CF lung disease is unclear. The presence of theStreptococcus millerigroup (SMG; also known as the anginosus group streptococci [AGS]) correlates with exacerbation when these microbes are the predominant species in the lung. In contrast, microbiome studies have indicated that an increased relative abundance of streptococci in the lung, including members of the oral microflora, correlates with impacts on lung disease less severe than those caused by other CF-associated microflora, indicating a complex role for this genus in the context of CF. Recent findings suggest that streptococci in the CF lung microenvironment may influence the growth and/or virulence of other CF pathogens, as evidenced by increased virulence factor production byPseudomonas aeruginosawhen grown in coculture with oral streptococci. Conversely, the presence ofP. aeruginosacan enhance the growth of streptococci, including members of the SMG, a phenomenon that could be exacerbated by the fact that streptococci are not susceptible to some of the frontline antibiotics used to treatP. aeruginosainfections. Collectively, these studies indicate the necessity for further investigation into the role of streptococci in the CF airway to determine how these microbes, alone or via interactions with other CF-associated pathogens, might influence CF lung disease, for better or for worse. We also propose that the interactions of streptococci with other CF pathogens is an ideal model to study clinically relevant microbial interactions.


Author(s):  
O.L. VORONINA ◽  
◽  
N.N. RYZHOVA ◽  
I.A. PRUDNIKOVA ◽  
M.S. KUNDA ◽  
...  

Author(s):  
Anne H. Neerincx ◽  
Katrine Whiteson ◽  
Joann L. Phan ◽  
Paul Brinkman ◽  
Mahmoud I. Abdel-Aziz ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document